Mareike Frick

Dr. Mareike Frick

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AHAdriane Halik
Adriane Halik
CAChristopher Maximilian Arends
Christopher Maximilian Arends
LBLars B. Bullinger
Lars B. Bullinger
FDFrederik Damm
Frederik Damm
MFMareike Frick
Mareike Frick
The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.

3 March 2022 in Haematologica
Verified
Journal Article
Open access
PDF file
JFJasper David Feldkamp
Jasper David Feldkamp
VVValentin Max Vetter
Valentin Max Vetter
CAChristopher Maximilian Arends
Christopher Maximilian Arends
TLTonio Johannes Lukas Lang
Tonio Johannes Lukas Lang
LBLars Bullinger
Lars Bullinger
MFMareike Frick
Mareike Frick

15 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TLTonio Johannes Lukas Lang
Tonio Johannes Lukas Lang
FDFrederik Damm
Frederik Damm
LBLars B. Bullinger
Lars B. Bullinger
MFMareike Frick
Mareike Frick
In recent years, great progress has been made in the therapy of AML by targeting cellular processes associated with specific molecular features of the disease. Various small molecules inhibiting FLT3, IDH1/IDH2, and BCL2 have already gained approval from the respective authorities and are essential parts of personalized therapeutic regimens in modern therapy of AML. Unfortunately, primary and secondary resistance to these inhibitors is a frequent problem. Here, we comprehensively review the current state of knowledge regarding molecular processes involved in primary and secondary resistance to these agents, covering both genetic and nongenetic mechanisms. In addition, we introduce concepts and strategies for how these resistance mechanisms might be overcome.

1 March 2012 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
MFMareike Frick
Mareike Frick
BDBernd Dörken
Bernd Dörken
GLGeorg Lenz
Georg Lenz

9 April 2026 in Blood
Verified
Journal Article
Closed access
LWLaura Wiegand
Laura Wiegand
PSPatricia Silva
Patricia Silva
DNDaniel Noerenberg
Daniel Noerenberg
FCFriederike Christen
Friederike Christen
KKKlara Kopp
Klara Kopp
FDFrederik Damm
Frederik Damm
The contribution of clonal hematopoiesis (CH) and disease-initiating precursors in B-cell non-Hodgkin lymphomas (B-NHLs) remains underexplored. Such precursors may drive clonal evolution, contributing to disease progression and relapse. Here, we systematically profiled genetic precursor lesions in 43 patients with B-NHL using complementary whole-exome, targeted, and single-cell sequencing approaches. CH-associated mutations with a variant allele frequency of ≥1% were detected in the peripheral blood of 55% of patients, with significantly higher frequencies in indolent compared with aggressive B-NHL (P = .03). Quantification of allele burden in flow-sorted cell populations revealed a B-cell–skewed expansion of CH clones, contrasting the myeloid differentiation bias reported in individuals without hematologic malignancies. Gene-specific expansion patterns were evident among the most frequent CH lesions, with DNMT3A-mutant clones exhibiting impaired hematopoietic differentiation and TET2-mutant clones having multilineage propagation. Notably, identical CH clones were detected in 41% of corresponding lymphomas, displaying distinct clonal dynamics: tumor-promoting CH (expansion in B-NHL; 10/16 clones; mainly TP53) and tumor-infiltrating CH (no expansion; mainly DNMT3A). Moreover, we identified lymphoma-associated mutations in flow-sorted hematopoietic progenitors from patients with indolent but not aggressive B-NHL and observed a stepwise accumulation of mutations along the lymphoid differentiation path. Single-cell genotyping confirmed the presence of mutated progenitors in 3 follicular, 2 mantle cell, and 2 marginal zone lymphoma patients, providing direct evidence of a preneoplastic state in disease pathogenesis. Our findings offer novel insight into the cellular origin of nodal B-NHLs and highlight a previously underappreciated role for early clonal events involving the stem/progenitor cell compartment.

3 June 2026 in Blood Advances
Verified
Journal Article
Open access
VZVanja Zeremski
Vanja Zeremski
SBSina Alexandra Beer
Sina Alexandra Beer
FDFrederik Damm
Frederik Damm
MFMareike Frick
Mareike Frick
THTobias Ronny Haage
Tobias Ronny Haage
DMDimitrios Mougiakakos
Dimitrios Mougiakakos